| Title |
Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway
|
|---|---|
| Published in |
Pharmacogenomics and Personalized Medicine, November 2014
|
| DOI | 10.2147/pgpm.s53163 |
| Pubmed ID | |
| Authors |
Parisa Momtaz, Michael A Postow |
| Abstract |
T-lymphocytes have the potential to recognize cancer antigens as foreign and therefore eliminate them. However, immune checkpoints such as cytotoxic T-lymphocyte-associated antigen (CTLA)-4 and programmed cell death (PD)-1 receptor and its ligands (PD-L1, PD-L2) suppress the activity of T-lymphocytes. Advances in the understanding of immunology and its role in cancer have led to the development of immune checkpoint inhibitors that block CTLA-4 and PD-1 and result in durable responses in patients with a wide range of cancers. PD-1 and PD-L1 inhibitors are currently in many stages of clinical investigation, and the anti-PD-1 antibody, pembrolizumab, was recently approved by the US Food and Drug Administration. Many questions remain to be answered, such as the optimal administration schedule, biomarkers that associate with benefit, and potential for use of PD-1 agents in combination approaches. Nonetheless, immunotherapy with PD-1 blocking antibodies is now becoming an integral part in the management of cancer. |
Mendeley readers
The data shown below were compiled from readership statistics for 140 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 1% |
| Japan | 2 | 1% |
| Denmark | 1 | <1% |
| Belgium | 1 | <1% |
| Korea, Republic of | 1 | <1% |
| Unknown | 133 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 37 | 26% |
| Student > Bachelor | 18 | 13% |
| Student > Master | 15 | 11% |
| Student > Ph. D. Student | 14 | 10% |
| Other | 10 | 7% |
| Other | 19 | 14% |
| Unknown | 27 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 44 | 31% |
| Agricultural and Biological Sciences | 23 | 16% |
| Biochemistry, Genetics and Molecular Biology | 16 | 11% |
| Immunology and Microbiology | 7 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 3% |
| Other | 14 | 10% |
| Unknown | 32 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 March 2024.
All research outputs
#3,874,929
of 25,748,735 outputs
Outputs from Pharmacogenomics and Personalized Medicine
#1
of 1 outputs
Outputs of similar age
#43,567
of 274,705 outputs
Outputs of similar age from Pharmacogenomics and Personalized Medicine
#1
of 1 outputs
Altmetric has tracked 25,748,735 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.0. This one scored the same or higher as 0 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 274,705 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them